Biocon closer to Europe approval of biosimilar pegfilgrastim
newsdepo.com
Amgen#39;s Neulasta had brand sales of more than $450 million in Europe for the 12 months ending June 30, 2018, according to market research firm IQVIA.Biocon closer to Europe approval of biosimilar pegfilgrastim
Amgen#39;s Neulasta had brand sales of more than $450 million in Europe for the 12 months ending June 30, 2018, according to market research firm IQVIA. Read more